2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. Post author:alarpharm Post published:3 . 5 . 2021 Post category:Media releases You Might Also Like 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020 2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 13 . 5 . 2022 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021 2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022 2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN. 13 . 5 . 2022
2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020
2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 13 . 5 . 2022
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022
2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN. 13 . 5 . 2022